IntelliPharmaCeutics International (IntelliPharmaCeutics International) Cash Flow from Financing : $0.00 Mil (TTM As of Aug. 2023)

View and export this data going back to 1996. Start your Free Trial

What is IntelliPharmaCeutics International Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Aug. 2023, IntelliPharmaCeutics International paid $0.00 Mil more to buy back shares than it received from issuing new shares. It received $0.00 Mil from issuing more debt. It paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares. It received $0.00 Mil from paying cash dividends to shareholders. It received $0.00 Mil on other financial activities. In all, IntelliPharmaCeutics International spent $0.00 Mil on financial activities for the three months ended in Aug. 2023.

IntelliPharmaCeutics International Cash Flow from Financing Historical Data

The historical data trend for IntelliPharmaCeutics International's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International Cash Flow from Financing Chart

IntelliPharmaCeutics International Annual Data

Trend

Nov13

Nov14

Nov15

Nov16

Nov17

Nov18

Nov19

Nov20

Nov21

Nov22

Cash Flow from Financing

Get a 7-Day Free Trial

17.36

0.10

3.03

0.20

IntelliPharmaCeutics International Quarterly Data
	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23
Cash Flow from Financing	Get a 7-Day Free Trial															-	-	-	-	-

IntelliPharmaCeutics International Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

IntelliPharmaCeutics International's Cash from Financing for the fiscal year that ended in Nov. 2022 is calculated as:

	Cash Flow from Financing		(A: Nov. 2022 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0.2	+	0	+	0	+	0
=	0.20

IntelliPharmaCeutics International's Cash from Financing for the quarter that ended in Aug. 2023 is:

	Cash Flow from Financing		(Q: Aug. 2023 )
=	Issuance of Stock	+	Repurchase of Stock	+	Net Issuance of Debt	+	Net Issuance of Preferred Stock	+	Cash Flow for Dividends	+	Other Financing
=	0	+	0	+	0	+	0	+	0	+	0
=	0.00

Cash Flow from Financing for the trailing twelve months (TTM) ended in Aug. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

IntelliPharmaCeutics International (OTCPK:IPCIF) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

IntelliPharmaCeutics International's issuance of stock for the three months ended in Aug. 2023 was $0.00 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

IntelliPharmaCeutics International's repurchase of stock for the three months ended in Aug. 2023 was $0.00 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

IntelliPharmaCeutics International's net issuance of debt for the three months ended in Aug. 2023 was $0.00 Mil. IntelliPharmaCeutics International received $0.00 Mil from issuing more debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

IntelliPharmaCeutics International's net issuance of preferred for the three months ended in Aug. 2023 was $0.00 Mil. IntelliPharmaCeutics International paid $0.00 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

IntelliPharmaCeutics International's cash flow for dividends for the three months ended in Aug. 2023 was $0.00 Mil. IntelliPharmaCeutics International received $0.00 Mil from paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

IntelliPharmaCeutics International's other financing for the three months ended in Aug. 2023 was $0.00 Mil. IntelliPharmaCeutics International received $0.00 Mil on other financial activities.

IntelliPharmaCeutics International Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.

IntelliPharmaCeutics International (IntelliPharmaCeutics International) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (OTCPK:IPCIF) » Definitions » Cash Flow from Financing

Comparable Companies

Traded in Other Exchanges

I4AA:Germany IPCI:Canada

Address

30 Worcester Road, Toronto, ON, CAN, M9W 5X2

Website

https://www.intellipharmaceutics.com

IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.